LifeCell International is a prominent Indian biotechnology company founded in 2004, primarily known for its extensive work in stem cell banking and related healthcare services. Company OverviewFoundation: Established in 2004, LifeCell International has become India's largest stem cell bank and is recognized as the third-largest globally.Core Services: The company specializes in umbilical cord blood stem cell banking, diagnostics, and tissue therapeutics. It aims to provide preventive healthcare services that enhance family wellness
| Financial Ratios | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Operating Profit Margin | - | - | - | - |
| Net Profit Margin | - | - | - | - |
| Earning Per Share (Diluted) | - | - | - | 10.9 |
| Assets | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Fixed Assets | 546.98 | 488.93 | 447.94 | 436.96 |
| CWIP | 29.47 | 26.05 | 22.2 | 20.53 |
| Investments | 398.91 | 16.45 | 10.04 | 3.89 |
| Trade Receivables | 469.09 | 213.27 | 70.97 | 72.12 |
| Inventory | 906.75 | 491.23 | 319.43 | 244.3 |
| Other Assets | 0 | 0 | 0 | 0 |
| Total Assets | 2,795.69 | 1,638.77 | 1,072.81 | 991.23 |
| Liabilities | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Share Capital | 10.02 | 10.02 | 10.02 | 10.02 |
| Reserves | 0.38 | 0.29 | -1.02 | -1.02 |
| Borrowings | 108 | 230 | 230 | - |
| Trade Payables | 0.01 | 0.01 | 0 | - |
| Other Liabilities | 0.03 | 0.01 | 0.02 | - |
| Total Liabilities | 10.51 | 10.33 | 9.03 | - |
| Cash-Flow Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| PBT | - | - | - | - |
| OPBWC | - | - | - | - |
| Change in Receivables | - | - | - | - |
| Change in Inventories | - | - | - | - |
| Change in Payables | - | - | - | - |
| Other Changes | - | - | - | - |
| Working Capital Change | - | - | - | - |
| Cash Generated From Operations | - | - | - | - |
| Tax | - | - | - | - |
| Cash Flow From Operations | - | - | - | - |
| Purchase of PPE | - | - | - | - |
| Sale of PPE | - | - | - | - |
| Cash Flow From Investment | - | - | - | - |
| Borrowing | - | - | - | - |
| Divided | - | - | - | - |
| Equity | - | - | - | - |
| Others From Financing | - | - | - | - |
| Cash Flow from Financing | - | - | - | - |
| Net Cash Generated | - | - | - | - |
| Cash at the Start | - | - | - | - |
| Cash at the End | - | - | - | - |
| Shareholding Pattern | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Foreign Holding | 0.79 | 0.79 | 0.79 | 0.79 |
| Others/Public & Other | 28.48 | 28.48 | 28.48 | 28.48 |
| Promoters | 70.73 | 70.73 | 70.73 | 70.73 |
